Comparative evaluation of 14 immunoassays for detection of antibodies to the human T-lymphotropic virus types I and II using panels of sera from Sweden and West Africa

Transfusion

Volumn 39, Issue 8, 1999, Pages 845-851

  Andersson, Sören ^a   Thorstensson, R ^b   Ramirez, K Godoy ^b   Krook, A ^b   Von Sydow, M ^b   Dias, F ^b   Biberfeld, G ^b  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AFRICA; ANTIBODY DETECTION; ANTIGEN SPECIFICITY; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; IMMUNOASSAY; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; PATIENT SELECTION; POLYMERASE CHAIN REACTION; PREDICTION; STATISTICAL ANALYSIS; SWEDEN;

AFRICA, WESTERN; DELTARETROVIRUS ANTIBODIES; EVALUATION STUDIES; FALSE NEGATIVE REACTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2; HUMANS; MASS SCREENING; SENSITIVITY AND SPECIFICITY; SWEDEN;

EID: 0033361160     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.1999.39080845.x     Document Type: Article

References (24)

1. Recommendations for counseling persons infected with human T-lymphotropic virus, types I and II. Centers for Disease Control and Prevention and U.S. Public Health Service Working Group. MMWR Morb Mortal Wkly Rep 1993;42(RR-9):1-13.
2. Murphy EL. HTLV-II-related disease. Lancet 1993;341:888.
3. Hall WW, Ishak R, Zhu SW, et al. Human T lymphotropic virus type II (HTLV-II): epidemiology, molecular properties, and clinical features of infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13(Suppl 1):S204-14.
4. Gessain A, Mahieux R, de The G. Genetic variability and molecular epidemiology of human and simian T cell leukemia/lymphoma virus type I.J Acquir Immune Defic Syndr Hum Retrovirol 1996;13(Suppl 1):S132-45.
5. Seroepidemiology of the human T-cell leukemia/lymphoma viruses in Europe. The HTLV European Research Network. J Acquir Immune Defic Syndr Hum Retrovirol 1996;3:68-77.
6. Wiktor SZ, Pate EJ, Weiss SH, et al. Sensitivity of HTLV-I antibody assays for HTLV-II (letter). Lancet 1991;338:512-3.
7. Soriano V, Calderon E, Gutierrez M, et al. Misdiagnosis of HTLV-II infection using HTLV-I screening assays. MMWR Morbidity and Mortality Weekly Report 1993;42(RR-9):1-13. AIDS 1993:7:1395.
8. Soriano V, Calderon E, Gutierrez M, et al. Misdiagnosis of HTLV-II infection using HTLV-I screening assays. MMWR Morbidity and Mortality Weekly Report 1993;42(RR-9):1-13. AIDS 1993:7:1395.
9. Hjelle B, Wilson C, Cyrus S, et al. Human T-cell leukemia virus type II infection frequently goes undetected in contemporary US blood donors. Blood 1993;81:1641-4.
10. Rios M, Khabbaz RF, Kaplan JE, et al. Transmission of human T cell lymphotropic virus (HTLV) type II by transfusion of HTLV-I-screened blood products. J Infect Dis 1994;170:206-10.
11. Henrard D, Soriano V, Robertson E, et al. Prevalence of human T-cell lymphotropic virus type 1 (HTLV-I) and HTLV-2 infection among Spanish drug users measured by HTLV-I assay and HTLV-1 and -2 assay. HTLV-1 and HTLV-2 Spanish Study Group. J Clin Microbiol 1995;33:1735-8.
12. Gallo D, Yeh E, Moore E, Hanson C. Comparison of four enzyme immunoassays for detection of human T-cell lymphotropic virus type 2 antibodies. J Clin Microbiol 1996;34:213-5.
13. Krook A, Albert J, Andersson S, et al. Prevalence and risk factors for HTLV-II infection in 913 injecting drug users in Stockholm, 1994. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15:381-6.
14. Constantine NT, Callahan JD, Watts DM. Retroviral testing: essentials for quality control and laboratory diagnosis. Boca Raton, FL: CRC Press, 1992.
15. Crofts N, Maskill W, Gust ID. Evaluation of enzyme-linked immunosorbent assays: a method of data analysis. J Virol Methods 1988;22:51-9.
16. Geigy scientific tables, vol 2. West Caldwell, NJ: CIBA-Geigy, 1982.
17. Tynell E, Andersson S, Lithander E, et al. Screening for human T cell leukaemia/lymphoma virus among blood donors in Sweden: cost effectiveness analysis. BMJ 1998;316:1417-22.
18. Andersson S, Dias F, Mendez PJ, et al. HTLV-I and -II infections in a nationwide survey of pregnant women in Guinea-Bissau, West Africa (letter). J Acquir Immune Defic Syndr Hum Retrovirol 1997;15:320-2.
19. Khabbaz RF, Hartley TM, Lairmore MD, Kaplan JE. Epidemiologic assessment of screening tests for antibody to human T lymphotropic virus type I (HTLV-I). Am J Public Health 1990;80:190-2.
20. Kline RL, Brothers T, Halsey N, et al. Evaluation of enzyme immunoassays for antibody to human T-lymphotropic viruses type I/II. Lancet 1991;337:30-3.
21. Cossen C, Hagens S, Fukuchi R, et al. Comparison of six commercial human T-cell lymphotropic virus type I (HTLV-I) enzyme immunoassay kits for detection of antibody to HTLV-I and -II. J Clin Microbiol 1992:30:724-5.
22. Vrielink H, Reesink HW, Zaaijer HL, et al. Sensitivity and specificity of four assays to detect human T-lymphotropic virus type I or type I/II antibodies. Transfusion 1996;36:344-6.
23. Operational characteristics of commercially available assays to determine antibodies to HlV-I and/or HIV-2 in human sera. Report 3. Global Programme on AIDS. Geneva: World Health Organization, March 1991.
24. Weiss S, Denny T, Quirinale J, et al. HTLV-II screening issues: false negative HTLV ELISA results within a high risk IDU cohort. AIDS Res Hum Retroviruses 1994;10:451.